Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407563 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
A Phase 2 study of Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 11
- Study locations
NCT00407563 is a Phase 2 study of Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 48 participants, below the 210-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (77% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT00407563, a Phase 2 study of Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Abraxane
Study Locations (11)
Georgia
- Northeast Georgia Cancer Care, LLC - Athens
- Southeastern Gynecologic Oncology, LLC - Atlanta
Tennessee
- Chattanooga's Program in Women's Oncology - Chattanooga
- The West Clinic - Memphis
Arkansas
- Little Rock Hematology Oncology - Little Rock
California
- Wilshire Oncology Medical Group, Inc. - La Verne
Idaho
- North Idaho Cancer Center - Coeur d'Alene
Montana
- Hematology-Oncology Centers of the Northern Rockies - Billings
Ohio
- Mid-Ohio Oncology/Hematology - Columbus
Pennsylvania
- Pennsylvania Oncology Hematology Assoc. - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00407563
The ClinicalTrials.gov registry entry for NCT00407563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00407563 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Georgia, Tennessee, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00407563 about?
NCT00407563 is a clinical study titled "Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer". The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.
What is the current status of trial NCT00407563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2007-01. Estimated completion is 2011-02.
What conditions does trial NCT00407563 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma.
What interventions are being tested in trial NCT00407563?
The interventions under investigation include: Bevacizumab (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT00407563?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00407563 being conducted?
This trial has 11 study locations across Arkansas, California, Georgia, Idaho, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Isoquercetin in People With Ovarian Cancer
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
COMPLETED · Phase 2
-
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.